The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
Abstract
PURPOSE: A systematic review of randomized clinical trials (RCTs) was undertaken to assess the effectiveness of medical treatment for metastatic breast cancer. METHODS: RCTs published between 1975 and 1997 have been classified according to 12 therapeutic comparisons: (1) polychemotherapy (PCHT) agents versus single agent; (2) PCHT regimens with anthracycline versus PCHT without anthracycline; (3) other PCHT versus cyclophosphamide, methotrexate, and fluorouracil (CMF); (4) chemotherapy (CHT) with epirubicin versus CHT with doxorubicin; (5) CHT versus same CHT delivered with less intensive schedules; (6) other endocrine therapy (OET) versus tamoxifen; (7) OET plus tamoxifen versus tamoxifen alone; (8) OET versus medroxyprogesterone; (9) OET versus aromatase inhibitors; (10) OET versus megestrol; (11) endocrine therapy (ET) versus same ET at lower doses; and (12) CHT plus ET versus CHT. Tumor response rates, mortality hazards ratio (HR) and frequency of severe side effects were the outcome measures. RESULTS: A total of 189 eligible trials (31,510 patients) were identified. All provided response rates and 133 (70%) data or survival curves needed for calculation of the HR. In eight of 12 comparisons, statistically significant differences for response emerged (1, 2, 3, 5, 7, 8, 11, 12); all but no. 8 favored the first term of the comparison. Overall survival analysis showed better results of (a) PCHT versus single-agent CHT (HR=0.82; 95% confidence interval [CI], 0.75 to 0.90); (b) CHT with doxorubicin versus CHT with epirubicin (HR=1.13; 95% CI, 1.00 to 1.27); (c) CHT versus the same CHT delivered with less intensive schedules (HR=0.90; 95% CI, 0.83 to 0.97); (d) ET versus the same ET at lower doses (HR=0.86; 95% CI, 0.77 to 0.97). Quality of life was measured in only 2,995 of 31,510 patients (9.5%). CONCLUSION: Despite some evidence of effectiveness of specific regimens, the relevance of these findings is limited by the modest survival benefit and the lack of evaluation of the quality-of-life impact of these treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bezwoda, W. R., Seymour, L., & Dansey, R. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2483 · Cited by 400
RetractedSTATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Self-citationSystemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Meta-analysis of the literature or of individual patient data: is there a difference?
Stewart, L. A., & Parmar, M. K. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)93004-k · Cited by 769
Pisani, P., Parkin, D. M., & Ferlay, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550604 · Cited by 583
Grégoire, G., Derderian, F., & Le Lorier, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00098-b · Cited by 526
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S., Larocque, G., Mayers, C., Perrault, D., & Sutherland, H. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.9.1377 · Cited by 348
Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J. H., Bisel, H. F., Kvols, L. K., Nichols, W. C., Creagan, E. T., Hahn, R. G., Rubin, J., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040104 · Cited by 336
Coates, A., Gebski, V, Signorini, D., Murray, P., McNeil, D., Byrne, M., & Forbes, J. F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1833 · Cited by 313
Jain, K. K., Casper, E. S., Geller, N. L., Hakes, T. B., Kaufman, R. J., Currie, V, Schwartz, W., Cassidy, C., Petroni, G. R., & Young, C. W. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.818 · Cited by 251
Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Mailliard, J. A., Jones, S. E., Vogel, C. L., Berris, R. F., & Shemano, I. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2556 · Cited by 216
Ingle, J. N., Krook, J. E., Green, S. J., Kubista, T. P., Everson, L. K., Ahmann, D. L., Chang, M. N., Bisel, H. F., Windschitl, H. E., & Twito, D. I. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.178 · Cited by 173
(1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.976 · Cited by 167
Fate of Cardiology Research Originally Published in Abstract Form
Goldman, L., & Loscalzo, A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198007313030504 · Cited by 160
Buchanan, R. B., Blamey, R. W., Durrant, K. R., Howell, A., Paterson, A. G., Preece, P. E., Smith, D. C., Williams, C. J., & Wilson, R. G. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.9.1326 · Cited by 159
Experimental and clinical results with intraperitoneal cisplatin.
Huinink, W. W. T. B., Dubbelman, R., Aartsen, E. J., Franklin, H. L., & Jg, M. (1985) · PubMed · Cited by 148
Boccardo, F., RUBAGOTTI, A., Perrotta, A., AMOROSO, D., Balestrero, M., Matteis, A. D., Zola, P., Sismondi, P., Francini, G., Petrioli, R., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058837 · Cited by 134
Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.
TORMEY, D. C., LIPPMAN, M. E., EDWARDS, B. K., & CASSIDY, J. G. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-2-139 · Cited by 128
Buzdar, A. U., Smith, R. A., Vogel, C. L., Bonomi, P., Keller, A. M., Favis, G., Mulagha, M. T., Cooper, J., & for the Multi-Institutional Trialist Collaborative Study Group (1996) · Cancer · Cited by 118
Habeshaw, T., Paul, J., Jones, R., Stallard, S., Stewart, M., Kaye, S. B., Soukop, M., Symonds, R. P., Reed, N., & Rankin, E. M. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.2.295 · Cited by 116
Pérez, D. J., Harvey, V. J., Robinson, B. A., Atkinson, C. H., Dady, P. J., Kirk, A. R., Evans, B. D., & Chapman, P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.12.2148 · Cited by 116
Tormey, D. C., Gelman, R. S., Band, P. R., Sears, M. E., Rosenthal, S. N., DeWys, W. D., Perlia, C. P., & Rice, M. A. (1982) · Cancer · Cited by 113
Bennett, J. M., Muss, H. B., Doroshow, J. H., Wolff, S., Krementz, E. T., Cartwright, K. J., Dukart, G., Reisman, A., & Schoch, I. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1611 · Cited by 109
Jonat, W., Kaufmann, M., Blamey, R. W., Howell, A., Collins, J. P., Coates, A., EIERMANN, W., Jänicke, F., Njordenskold, B., Forbes, J., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00415-2 · Cited by 103
Carrion, R. P., Candel, V. A., Calabresi, F., Michel, R. T., dos Santos, R. B., Delozier, T., Goss, P. E., Mauriac, L., Feuilhade, F., & Freue, M. (1994) · PubMed · Cited by 99
Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial
Stenbygaard, L. E., Herrstedt, J., Thomsen, J. F., et al. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00662401 · Cited by 95
Thurlimann, B. J. K., Beretta, K., Bacchi, M., Castiglione‐Gertsch, M., Goldhirsch, A., Jungi, W. F., Cavalli, F., Senn, H.-J., Fey, M. F., & Löhnert, T. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010635 · Cited by 95
Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla, C., Rossi, A., Bonfante, V., Ferrari, L., Villani, F., Crippa, F., & Bonadonna, G. (1986) · PubMed · Cited by 94
Smith, I. E., Harris, A. L., Morgan, M., Gazet, J. C., & McKinna, J. A. (1982) · PubMed · Cited by 92
A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer
Lipton, A., Harvey, H. A., Santen, R. J., Boucher, A. E., White, D., Bernath, A. M., Dixon, R. H., Richards, G., & Shafik, A. (1982) · Cancer · doi:10.1002/1097-0142(19821201)50:11<2265::aid-cncr2820501106>3.0.co;2-# · Cited by 91
Smalley, R. V., Lefante, J. J., Bartolucci, A. A., Carpenter, J. T., Vogel, C. L., & Krauss, S. (1983) · Breast Cancer Research and Treatment · doi:10.1007/bf01803563 · Cited by 90
A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer
Hortobágyi, G. N., Yap, H. Y., Kau, S., Fraschini, G., Ewer, M. S., Chawla, S. P., & Benjamin, R. S. (1989) · American Journal of Clinical Oncology · doi:10.1097/00000421-198902000-00014 · Cited by 88
Treatment of metastatic breast cancer: present and future prospects.
Hayes, D. F., Henderson, I. C., & Shapiro, C. (1995) · PubMed · Cited by 79
Kornblith, A. B., Hollis, D. R., Zuckerman, E., Lyss, A. P., Canellos, G. P., Cooper, M. R., Herndon, J. E., Phillips, C. A., Abrams, J. S., & Aisner, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2081 · Cited by 78
Muss, H. B., Wells, H. B., Paschold, E., Black, W. R., Cooper, M. R., Capizzi, R. L., Christian, R., Cruz, J. M., Jackson, D. V., & Powell, B. L. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.7.1098 · Cited by 77
Ingle, J. N., Ahmann, D. L., Green, S., Edmonson, J. H., Creagan, E. T., Hahn, R. G., & Rubin, J. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198204000-00062 · Cited by 73
Muss, H. B., Case, L. D., Capizzi, R. L., Cooper, M. R., Cruz, J. M., Jackson, D. V., Richards, F., Powell, B. L., Spurr, C. L., & White, D. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1797 · Cited by 73
Muss, H. B., Case, L. D., Atkins, J., Bearden, J. D., Cooper, M. R., Cruz, J. M., Jackson, D. V., O’Rourke, M. A., Pavy, M. D., & Powell, B. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1630 · Cited by 70
Raats, J., Falkson, G., & Hc, F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.111 · Cited by 67
Falkson, C. I., & Hc, F. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010634 · Cited by 66
della Cuna, G. R., Calciati, A., Strada, M. R., et al. (1978) · Tumori Journal · doi:10.1177/030089167806400204 · Cited by 66
Beex, L. V. A. M., PIETERS, G. F. F. M., SMALS, A. G. H., Koenders, A., Benraad, T. J., & KLOPPENBORG, P. W. C. (1981) · PubMed · Cited by 64
Ingle, J. N., JOHNSON, P. A., Suman, V. J., Gerstner, J. B., Mailliard, J. A., Camoriano, J. K., Gesme, D. H., Loprinzi, C. L., Hatfield, A. K., & Hartmann, L. C. (1997) · Cancer · Cited by 63
Conte, P., Pronzato, P., RUBAGOTTI, A., Alama, A., Amadori, D., Demicheli, R., Gardin, G., Gentilini, P., Jacomuzzi, A., & Lionetto, R. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.3.339 · Cited by 62
Richards, M. A., Hopwood, P., Ramirez, A. J., Twelves, C. J., Ferguson, J., Gregory, W. M., Swindell, R., Scrivener, W., Miller, J. E., Howell, A., et al. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90447-a · Cited by 60
Dibromodulcitol and Adriamycin ± tamoxifen in advanced breast cancer*
Tormey, D. C., Falkson, G., Crowley, J. J., Hc, F., Voelkel, J. G., & Davis, T. E. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198202000-00006 · Cited by 58
Ingle, J. N., Green, S., Ahmann, D. L., Long, H. J., Edmonson, J. H., Rubin, J., Chang, M. N., & Creagan, E. T. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.6.958 · Cited by 58
Ht, M., Ellemann, K., Mattsson, W., Palshof, T., Daehnfeldt, J. L., & Rose, C. (1979) · PubMed · Cited by 57
Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial
Gundersen, S., Kvinnsland, S., Klepp, O., Kvaløy, S., Lund, E., & Høst, H. (1986) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(86)90075-1 · Cited by 56
Willemse, P. H. B., Ploeg, E. V. D., Sleijfer, D. T., Tjabbes, T., & van Veelen, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90231-h · Cited by 54
Gasparini, G., Fior, S. D., Panizzoni, G. A., Favretto, S., & Pozza, F. (1991) · American Journal of Clinical Oncology · doi:10.1097/00000421-199102000-00009 · Cited by 53
Recent advances in endocrine therapy of breast cancer
Howell, A., & Dowsett, M. (1997) · BMJ · doi:10.1136/bmj.315.7112.863 · Cited by 51
Bonneterre, J. M., Mauriac, L., Weber, B. E., Roche, H. H., Fargeot, P., Tubiana-Hulin, M., Sevin, M., Chollet, P. J. M., & Cappelaere, P. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90097-1 · Cited by 48
Gill, P. G., Gebski, V., Snyder, R. D., Burns, I., Levi, J. A., Byrne, M., & Coates, A. S. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058658 · Cited by 44
Batel-Copel, L., Kornblith, A. B., Batel, P. C., & Holland, J. C. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00414-5 · Cited by 42
Ettinger, D. S., Allegra, J. C., Bertino, J. R., Bonomi, P., Browder, H. P., Byrne, P. J., Carpenter, J. T., Catalano, R. B., Creech, R. H., & Dana, B. W. (1986) · PubMed · Cited by 40
Lopez, M., Papaldo, P., Lauro, L. D., Vici, P., Carpano, S., & Conti, E. (2009) · Oncology · doi:10.1159/000226671 · Cited by 39
Alonso, M. C., Ojeda-González, M. B., Beltran-Fabregat, M., Ribugent, J. D., López-López, L., Borrás-Balada, J., Cardenal-Alemany, F., Gómez‐Batiste, X., Fabregat-Mayol, J., & Viladiu-Quemada, P. (2009) · Oncology · doi:10.1159/000226639 · Cited by 39
Mouridsen, H. T., Rose, C., Engelsman, E., Sylvester, R. J., & Rotmensz, N. (1985) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(85)90128-2 · Cited by 38
Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Harvey, H. A., Lipton, A., White, D., Santen, R. J., Boucher, A. E., Shafik, A., & Dixon, R. (1982) · PubMed · Cited by 37
Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer
Matelski, H., Huberman, M. S., Zipoli, T. E., Greene, R., & Lokich, J. J. (1985) · American Journal of Clinical Oncology · doi:10.1097/00000421-198504000-00004 · Cited by 37
Ingle, J. N., Long, H. J., Loprinzi, C. L., Mailliard, J. A., Schaid, D. J., Krook, J. E., Dalton, R. J., Gesme, D. H., Windschitl, H. E., Pfeifle, D. M., et al. (1991) · Cancer · Cited by 37
High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer
Gallagher, C. J., Cairnduff, F., & Smith, I. E. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90056-3 · Cited by 37
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer
Bonnefoi, H. R., Smith, I. E., Dowsett, M., Trunet, P., Houston, S., da Luz, R., Rubens, R., Coombes, R. C., & Powles, T. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.93 · Cited by 32
Chlebowski, R. T., & Lillington, L. M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1789 · Cited by 31
New treatments for breast cancer.
Smith, G. A., & Henderson, I. C. (1996) · PubMed · Cited by 31
Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
Westerberg, H. (1980) · PubMed · Cited by 29
Heidemann, E., Steinke, B., Hartlapp, J. H., Schumacher, K. R., Possinger, K., Kunz, S., Neeser, E., Ingersleben, G. V., Hossfeld, D., & Waldmann, R. (2009) · Onkologie · doi:10.1159/000216714 · Cited by 29
Gockerman, J. P., Spremulli, E. N., Raney, M. R., & Logan, T. F. (1986) · PubMed · Cited by 28
Alonso, M. C., Tabernero, J. M., Ojeda, B., Llanos, M., Sol�, C., Climent, M. A., Seguí, M. Á., & L�pez, J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666487 · Cited by 27
Ebbs, S. R., Saunders, J. A., Graham, H., A’Hern, R., Bates, T., & Baum, M. (1989) · Acta Oncologica · doi:10.3109/02841868909092326 · Cited by 27
Epirubicin or epirubicin and vindesine in advanced breast cancer. A Phase III study
Nielsen, D. L., Dombernowsky, P., Skovsgaard, T., Jensen, J. B., Andersen, E., Engelholm, S., & Hansen, M. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057748 · Cited by 27
Paterson, A. H., Hanson, J., Pritchard, K. I., Sansregret, E., Dahrouge, S., McDermot, R. S. R., Fine, S., Df, W., Trudeau, M., & Dj, S. (1990) · PubMed · doi:10.5555/uri:pii:009377549090009r · Cited by 25
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer
Bajetta, E., Zilembo, N., Buzzoni, R., et al. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.265 · Cited by 24
Milsted, R., Habeshaw, T., Kaye, S. B., Sangster, G., Macbeth, F. R., Campbeli-Ferguson, J., Smith, D. C., & Calman, K. C. (1985) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00258132 · Cited by 22
Mouridsen, H. T., Palshof, T., & Rose, C. (1980) · Springer eBooks · doi:10.1007/978-3-642-81406-8_26 · Cited by 20
Gundersen, S., Kvinnsland, S., Klepp, O., Lund, E., & Høst, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90255-r · Cited by 18
Metastatic breast cancer: preliminary results with oral hormonal therapy.
Allegra, J. C., Bertino, J., Bonomi, P., Byrne, P., Carpenter, J. T., Catalano, R. B., Creech, R. H., Dana, B. W., Durivage, H. J., & Einhorn, L. H. (1985) · PubMed · Cited by 17
Periti, P., Pannuti, F., della Cuna, G. R., Mazzei, T., Mini, E., Martoni, A. A., Preti, P., Ercolino, L., Pavesi, L., & Ribecco, A. S. (1991) · Cancer Investigation · doi:10.3109/07357909109021321 · Cited by 17
Bruning, P. F., Bonfrer, J. M. G., Hart, A. A. M., van der Linden, E., Jong‐Bakker, M. D., Moolenaar, A. J., & Nooijen, W. J. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90032-1 · Cited by 17
Ceci, G., Bisagni, G., Cocconi, G., Rodinò, C., Belsanti, V., Bertusi, M., Buzzi, F., & Bacchi, M. (1995) · Tumori Journal · doi:10.1177/030089169508100405 · Cited by 15
Mercer, P. M., Ebbs, S. R., Fraser, S. C. A., Coltart, R. S., & Bates, T. (1993) · PubMed · Cited by 12
Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer
Heinonen, E., Alanko, A., Gröhn, P., & Rissanen, P. M. (1985) · Breast Cancer Research and Treatment · doi:10.1007/bf01807653 · Cited by 9
Ingle (1991) · doi:10.1002/1097-0142(19910215)67:4
Cited by
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
“analyzed (%) «1 48/143 (34) 49/136 (36) 31/91 (34) 27/95 (28) 2 38/143 (27) 48/136 (35) 32/91 (35) 35/95 (37) »3 57/143 (40) 39/136 (29) 28/91 (31) 33/95 (35)”
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 707
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Metadata
- Authors
- Fossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-10
- Volume
- 16
- Issue
- 10
- Pages
- 3439-3460
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2169073956
- Cited by
- 546
- References
- 87
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.